Navigation Links
Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
Date:1/28/2013

CHARLESTON, South Carolina, 28. Januar 2013 /PRNewswire/ -- Charleston Laboratories, Inc., ein aufstrebendes Pharmaunternehmen, das sich auf die Erforschung und Entwicklung neuartiger Schmerzmittel zur Verhinderung oder wesentlichen Minderung von Übelkeit und Erbrechen im Zusammenhang mit Opioidanalgetika und anderen Schmerzerkrankungen spezialisiert hat, gab heute bekannt, dass die Aufnahme von Patienten für die entscheidende der klinische Phase 3-Studie des Unternehmens für sein erstes Produkt, CL-108, zur Behandlung von mäßigen bis starken Schmerzen, begonnen hat.

„Der Beginn dieser Studie markiert den Höhepunkt der Arbeit zahlreicher Mitarbeiter", sagte Dr. Bernard P. Schachtel , Chief Scientific Officer von Charleston . „Neben den Informationen unserer wissenschaftlichen, klinischen und regulatorischen Berater haben auch die Prüfarzte in den Forschungszentren, in denen die Studie durchgeführt wird, etwas zum Protokoll beigetragen." Dr. Schachtel betonte insbesondere den Rat von Dr. Elliot V. Hersh , Professor für Mund-, Kiefer-, Gesichtschirurgie und Pharmakologie an der University of Pennsylvania, wo Dr. Hersh Forschungsleiter der Studie ist. „Wie die Begeisterung und der Einsatz der vielen Ärzte, Krankenschwestern, Studienkoordinatoren und anderen Forschern anlässlich unserer letzten Forschertagung gezeigt haben", fuhr Dr. Schachtel fort, „bietet diese Studie die seltene und spannende Gelegenheit, eine wirklich neue Indikation zur Behandlung von mäßigen bis schweren Schmerzen und die Übelkeit und das Erbrechen, das damit einhergeht, zu finden."

„Dieser Tag ist ein wichtiger Meilenstein für das Bestreben von Charleston, differenzierte und innovative Schmerzm
'/>"/>

SOURCE Charleston Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
2. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
3. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
4. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
5. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
6. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
7. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
8. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Phase 3 Topical Drug for Raynauds Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
(Date:12/24/2014)... 23, 2014 Echo Therapeutics, Inc. (NASDAQ: ... focused on skin permeation, continuous glucose monitoring and ... Hollander has been appointed Chief Executive Officer ... than 20 years of experience in the medical ... recently served as Vice President, Business Development, Otsuka ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... But effect for women not same, as study cites obesity ... Vitamin K slows the development of insulin resistance in older ... resistance, a precursor to diabetes, occurs when the body cannot ... the blood. Overweight and obese people are prone to insulin ...
... 5 MetLife Mexico, Mexico City, Mexico, the largest ... a leading provider of such services to individual and ... Assist America, Inc., Princeton, N.J., the premier provider of ... 500,000 of its insureds with emergency travel assistance. ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... $0.185 per share on the company,s common stock, a ... per share. The dividend,is payable Dec. 31, 2008, to ... 17, 2008. Hillenbrand has paid quarterly dividends since its ...
... BlueShield today,announced that its employees committed more than $1 ... This amount is the,result of personal giving by ... Inc. , "In ... especially in need of help," said Mark Wagar, president ...
... heart problems, study says , , FRIDAY, Dec. 5 (HealthDay News) ... (IPF) are three times more likely than people without the ... attack, according to a British study. , "If you ... a threefold increased risk of acute coronary syndrome, which is ...
... 5 CANTEL MEDICAL CORP. (NYSE: ... diluted share, on a 7% increase in sales to $64,406,000 ... $0.02 of expenses related to the relocation of our Dutch ... income of $1,939,000, or $0.12 per diluted share, on sales ...
Cached Medicine News:Health News:Vitamin K Slows Insulin Resistance in Older Men 2Health News:MetLife Mexico Life Insurance Company Partners with Assist America for Global Emergency Medical Assistance Services 2Health News:Empire BlueCross BlueShield Associates Commit Over $1 Million to Community Organizations in 2008 2Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 2Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 3Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 4Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 5Health News:Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008 6
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: